JP6976254B2 - Ｃｄ−ｒａｐ前駆体タンパク質の使用による、ｃｄ−ｒａｐの製造方法における発現およびフォールディングの改善 - Google Patents

Ｃｄ−ｒａｐ前駆体タンパク質の使用による、ｃｄ−ｒａｐの製造方法における発現およびフォールディングの改善 Download PDF

Info

Publication number
JP6976254B2
JP6976254B2 JP2018534009A JP2018534009A JP6976254B2 JP 6976254 B2 JP6976254 B2 JP 6976254B2 JP 2018534009 A JP2018534009 A JP 2018534009A JP 2018534009 A JP2018534009 A JP 2018534009A JP 6976254 B2 JP6976254 B2 JP 6976254B2
Authority
JP
Japan
Prior art keywords
rap
certain embodiments
seq
sequence
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018534009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527030A5 (enExample
JP2018527030A (ja
Inventor
シェットレ イザベル
シュトメス ユーディト
ハーバーマン パウル
ヤノハ ベアント
シュティルガー ウアズラ
バートニク エッカート
イェスケ フォルカー
ザース ヨアヒム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionet Pharma GmbH
Original Assignee
Bionet Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionet Pharma GmbH filed Critical Bionet Pharma GmbH
Publication of JP2018527030A publication Critical patent/JP2018527030A/ja
Publication of JP2018527030A5 publication Critical patent/JP2018527030A5/ja
Application granted granted Critical
Publication of JP6976254B2 publication Critical patent/JP6976254B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018534009A 2015-09-18 2016-09-16 Ｃｄ−ｒａｐ前駆体タンパク質の使用による、ｃｄ−ｒａｐの製造方法における発現およびフォールディングの改善 Expired - Fee Related JP6976254B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15306457 2015-09-18
EP15306458 2015-09-18
EP15306458.9 2015-09-18
EP15306457.1 2015-09-18
EP15306950 2015-12-07
EP15306950.5 2015-12-07
PCT/EP2016/071947 WO2017046314A2 (en) 2015-09-18 2016-09-16 Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein

Publications (3)

Publication Number Publication Date
JP2018527030A JP2018527030A (ja) 2018-09-20
JP2018527030A5 JP2018527030A5 (enExample) 2019-10-17
JP6976254B2 true JP6976254B2 (ja) 2021-12-08

Family

ID=57223637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018534009A Expired - Fee Related JP6976254B2 (ja) 2015-09-18 2016-09-16 Ｃｄ−ｒａｐ前駆体タンパク質の使用による、ｃｄ−ｒａｐの製造方法における発現およびフォールディングの改善

Country Status (8)

Country Link
US (2) US10660852B2 (enExample)
EP (1) EP3350204A2 (enExample)
JP (1) JP6976254B2 (enExample)
CN (1) CN108602866A (enExample)
AU (2) AU2016321884B2 (enExample)
CA (1) CA2998665A1 (enExample)
TW (1) TW201726712A (enExample)
WO (1) WO2017046314A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210219569A1 (en) * 2018-03-16 2021-07-22 Eco-Geo Bio-Technology Company Limited Use and composition of buffer formulation with multiple ph values and protein digestion enhancer
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
FR3092339B1 (fr) * 2019-02-05 2024-04-12 Michelin & Cie Cellule, notamment levure, resistante au phloroglucinol
JP7508359B2 (ja) 2020-12-11 2024-07-01 株式会社東芝 脂質粒子の製造方法
CN113024675A (zh) * 2020-12-29 2021-06-25 山东第一医科大学(山东省医学科学院) 一种hb-nc4重组蛋白及其制备方法与应用
CN116106399A (zh) * 2023-01-06 2023-05-12 浙江大学 一种研究果实蛋白质n-糖基化的整合分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95495A (en) * 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
AU5705600A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Novel polypeptide and dna thereof
JP4579378B2 (ja) * 1999-06-30 2010-11-10 武田薬品工業株式会社 新規ポリペプチドおよびそのｄｎａ
EP1604693A1 (en) 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
PL2081551T3 (pl) * 2006-10-06 2013-06-28 Scil Tech Gmbh Wytworzenie wysuszonego rekonstytuowanego pęcherzyka do zastosowania farmaceutycznego
EP2547700A1 (en) * 2010-03-17 2013-01-23 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
WO2011134979A2 (en) * 2010-04-27 2011-11-03 Scil Technology Gmbh Stable mia/cd-rap formulation

Also Published As

Publication number Publication date
CN108602866A (zh) 2018-09-28
AU2016321884A1 (en) 2018-04-12
TW201726712A (zh) 2017-08-01
JP2018527030A (ja) 2018-09-20
EP3350204A2 (en) 2018-07-25
WO2017046314A2 (en) 2017-03-23
WO2017046314A3 (en) 2017-05-26
CA2998665A1 (en) 2017-03-23
US20200268663A1 (en) 2020-08-27
US10660852B2 (en) 2020-05-26
US20190046442A1 (en) 2019-02-14
AU2016321884B2 (en) 2021-01-07
AU2021202110A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
US20200268663A1 (en) Expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein
US20250114406A1 (en) Methods and compositions relating to chondrisomes from blood products
Cao et al. A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice
Zheng et al. Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death
JP5989641B2 (ja) リポタンパク質製剤及びその製造方法
Kusma et al. Nephrotoxicity caused by brown spider venom phospholipase-D (dermonecrotic toxin) depends on catalytic activity
EA011586B1 (ru) Новый карбамилированный еро и способ его получения
Liu et al. Membrane localization of β-amyloid 1–42 in lysosomes: a possible mechanism for lysosome labilization
JP4387101B2 (ja) 糖尿病性網膜症の予防または処置のための網膜細胞アポトーシス抑制剤の使用
US20230132093A1 (en) Extracellular vesicle-nlrp3 antagonist
RU2711531C2 (ru) Средство для лечения фиброза почек
US20120156180A1 (en) Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
US20230193274A1 (en) Extracellular vesicles with stat3-antisense oligonucleotides
US20230002764A1 (en) Extracellular vesicle-aso constructs targeting cebp/beta
Niyitegeka et al. Isoform-specific interactions between meprin metalloproteases and the catalytic subunit of protein kinase A: significance in acute and chronic kidney injury
WO2025054501A1 (en) Modified silk fibroin and medical uses thereof
Malishev et al. Bacoside-A, an anti-amyloid natural substance, inhibits membrane disruption by the amyloidogenic determinant of prion protein through accelerating fibril formation
US10441541B2 (en) Methods and compositions for treating osteoarthritis and promoting cartilage formation
WO2014194428A1 (en) Targeted heparan sulfatase compounds
Sun et al. An engineering-reinforced hypoxia-preconditioned exosome-integrated hydrogel delays intervertebral disc degeneration via the PPARγ-autophagy axis
JP2008510476A (ja) 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
Tsiroulnikov et al. Phospholipids influence the aggregation of recombinant ovine prions: From rapid extensive aggregation to amyloidogenic conversion
US20260027147A1 (en) Extracellular vesicle-aso constructs targeting cebp/beta
US12214076B2 (en) Drug delivery vehicles for atherosclerosis nanomedicine
Campeiro Potential applications of the cell-penetrating peptide crotamine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211109

R150 Certificate of patent or registration of utility model

Ref document number: 6976254

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees